Life sciences · Journal article
Communications Biology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Persistent high-risk human papillomavirus (hrHPV) infections are the principal cause of cervical cancer, and are increasingly associated with ecological instability of the cervicovaginal microbiome. Multiomics studies indicate that hrHPV persistence is linked to reduced Lactobacillus dominance, increased anaerobic taxa, and metabolic alterations that may compromise epithelial integrity and antiviral immunity. In this Perspective article, we introduce a sequential microbiome therapy (SMT) framework designed to restore cervicovaginal ecological balance and support viral clearance. SMT is a two-phase, strain-resolved strategy. The first phase targets dysbiotic communities using antimicrobials, biofilm-disrupting or microbiota-modulating approaches to create a window for ecological reset. The second phase introduces health-associated Lactobacillus species selected for their acidification capacity, competitive fitness, and ability to stabilize the mucosal environment. We outline the ecological principles underpinning SMT and discuss its development as a potentially scalable microbiome-directed strategy for restoring cervicovaginal health and managing hrHPV-associated disease within existing cervical cancer prevention frameworks.